
Anorexia - Pipeline Insight, 2025
Description
DelveInsight’s, “Anorexia – Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Anorexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Anorexia: Overview
Anorexia Nervosa is a serious eating disorder that is treatable but can be life-threatening without intervention. With over 200,000 individuals in the United States impacted per year and the highest mortality rate of any mental illness, it is important to learn the signs, symptoms, and treatment options for this disorder. Anorexia Nervosa is characterized by the National Institute of Mental Illness as individuals that have “a significant and persistent reduction in food intake leading to extremely low body weight; a relentless pursuit of thinness; a distortion of body image and intense fear of gaining weight; and extremely disturbed eating behavior. Anorexia has no single cause. it seems that a genetic predisposition is necessary but not sufficient for development of the disorder. A positive diagnosis of psychologically driven weight loss can be made in most patients, without the need for a battery of complex investigations to reach a diagnosis of exclusion. Basic medical investigations, blood tests, electrocardiography, weighing, and measuring the patient provide an opportunity for the patient to return (to discuss the results) and can uncover psychological problems.
Strategies include:
This segment of the Anorexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anorexia Emerging Drugs
Further product details are provided in the report……..
Anorexia: Therapeutic Assessment
This segment of the report provides insights about the different Anorexia drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Anorexia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anorexia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anorexia drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Anorexia: Overview
Anorexia Nervosa is a serious eating disorder that is treatable but can be life-threatening without intervention. With over 200,000 individuals in the United States impacted per year and the highest mortality rate of any mental illness, it is important to learn the signs, symptoms, and treatment options for this disorder. Anorexia Nervosa is characterized by the National Institute of Mental Illness as individuals that have “a significant and persistent reduction in food intake leading to extremely low body weight; a relentless pursuit of thinness; a distortion of body image and intense fear of gaining weight; and extremely disturbed eating behavior. Anorexia has no single cause. it seems that a genetic predisposition is necessary but not sufficient for development of the disorder. A positive diagnosis of psychologically driven weight loss can be made in most patients, without the need for a battery of complex investigations to reach a diagnosis of exclusion. Basic medical investigations, blood tests, electrocardiography, weighing, and measuring the patient provide an opportunity for the patient to return (to discuss the results) and can uncover psychological problems.
Strategies include:
- cognitive-behavioral therapy (CBT), which can help the person find new ways of thinking, behaving, and managing stress
- family and individual counseling, as appropriate
- nutritional therapy, which provides information on how to use food to build and maintain health
- medication to treat depression and anxiety
- supplements to resolve nutritional deficiencies
- hospital treatment, in some cases
This segment of the Anorexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anorexia Emerging Drugs
- ART2713: Artelo Biosciences
Further product details are provided in the report……..
Anorexia: Therapeutic Assessment
This segment of the report provides insights about the different Anorexia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Anorexia
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III )
- Mid-Stage products (Phase II)
- Early-stage products ( Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Oral
- Molecule Type
- Small molecules
- Peptide
- Antibiotics
- Product Type
Anorexia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anorexia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anorexia drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Anorexia R&D. The therapies under development are focused on novel approaches to treat/improve Anorexia.
- Anorexia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Anorexia drugs?
- How many Anorexia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anorexia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anorexia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Anorexia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Amgen
- COMPASS Pathways
- Benuvia Therapeutics
- Artelo Biosciences
- RaQualia Pharma
- Receptor Life Sciences
- Pfizer
- Romosozumab
- Psilocybin
- RQ 00433412
- ART 2713
- PF-07258669
Table of Contents
50 Pages
- Introduction
- Executive Summary
- Anorexia: Overview
- ● Causes
- ● Mechanism of Action
- ● Signs and Symptoms
- ● Diagnosis
- ● Disease Management
- Pipeline Therapeutics
- ● Comparative Analysis
- Therapeutic Assessment
- ● Assessment by Product Type
- ● Assessment by Stage and Product Type
- ● Assessment by Route of Administration
- ● Assessment by Stage and Route of Administration
- ● Assessment by Molecule Type
- ● Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
- ● Comparative Analysis
- Drug Name: Company Name
- ● Product Description
- ● Research and Development
- ● Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase I/II)
- ● Comparative Analysis
- ART2713: Artelo Biosciences
- ● Product Description
- ● Research and Development
- ● Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- ● Comparative Analysis
- RQ 00433412: RaQualia Pharma
- ● Product Description
- ● Research and Development
- ● Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- ● Comparative Analysis
- Anorexia Key Companies
- Anorexia Key Products
- Anorexia- Unmet Needs
- Anorexia- Market Drivers and Barriers
- Anorexia- Future Perspectives and Conclusion
- Anorexia Analyst Views
- Anorexia Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.